Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-18
2011-01-18
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000, C544S298000, C544S408000, C546S242000, C549S398000
Reexamination Certificate
active
07872009
ABSTRACT:
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula Iwherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
REFERENCES:
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5712130 (1998-01-01), Hajko et al.
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6864290 (2005-03-01), Schostarez et al.
patent: 6982264 (2006-01-01), John et al.
patent: 6992103 (2006-01-01), Faller et al.
patent: 7067542 (2006-06-01), Schostarez et al.
patent: 7074799 (2006-07-01), Bakthavatchalam et al.
patent: 7109217 (2006-09-01), Coburn et al.
patent: 7115652 (2006-10-01), Yang
patent: 7115747 (2006-10-01), Reeder et al.
patent: 7132568 (2006-11-01), Yang et al.
patent: 7176242 (2007-02-01), John et al.
patent: 7223774 (2007-05-01), Aquino et al.
patent: 7244755 (2007-07-01), Fisher et al.
patent: 7253198 (2007-08-01), Demont et al.
patent: 7291620 (2007-11-01), Coburn et al.
patent: 7312360 (2007-12-01), TenBrink et al.
patent: 7348448 (2008-03-01), Nantermet et al.
patent: 7351738 (2008-04-01), Pulley et al.
patent: 7371853 (2008-05-01), Coburn et al.
patent: 2003/0109559 (2003-06-01), Gailunas et al.
patent: 2003/0166580 (2003-09-01), Warpehoski et al.
patent: 2004/0180939 (2004-09-01), John et al.
patent: 2005/0027007 (2005-02-01), Hom
patent: 2005/0038019 (2005-02-01), Beck
patent: 2005/0054690 (2005-03-01), Aquino et al.
patent: 2005/0267199 (2005-12-01), Hom et al.
patent: 2006/0211740 (2006-09-01), Demont et al.
patent: 2006/0229302 (2006-10-01), Demont et al.
patent: 2006/0241133 (2006-10-01), Shearman et al.
patent: 00/17369 (2000-03-01), None
patent: 01/70671 (2001-09-01), None
patent: 02/02505 (2002-01-01), None
patent: 03/002518 (2003-01-01), None
patent: 2004/099376 (2004-11-01), None
patent: 2005/058915 (2005-06-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 and 365.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker (Modern Pharmaceutics) Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Berge, et al., “Pharmaceutical Salts”, J. of Pharmaceutical Sciences, 66(1), 1-19 (1977).
Citron, M., “β-Secretase Inhibition for the Treatment of Alzheimer's Disease—Promise and Challenge”, Trends in Pharmacological Sciences, 25(2), 92-97 (2004).
Corey, et al., “The Application of a Mechanistic Model Leads to the Extension of the Sharpless Asymmetric Dihydroxylation to Allylic 4-Methoxybenzoates and Conformationally Related Aine and Homoallylic Alcohol Derivatives”, J. of Am. Chem. Soc., 117, 10805-10816 (1995).
Joachim, et al., “The Seminal Role of β-Amyloid in the Pathogenesis of Alzheimer Disease”, Alzheimer Disease and Associated Disorders, 6(1), 7-34 (1992).
Luo, et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”, Nature Neuroscience, 4(3), 231-232 (2001).
Reynaud, et al., “New Synthesis of the Thiazole Ring”, Bulletin de la Societe chimique de France, 1735-1738 (1962).
Sabbagh, et al.,“β-Amyloid and Treatment Opportunities for Alzheimer's Disease”, Alzheimer's Disease Review, 3, 1-19 (1998).
Selkoe, D.M., “The Molecular Pathology of Alzheimer's Disease”, Neuron, 6, 487-498 (1991).
Seubert, et al., “Isolation and Quantification of Soluble Alzheimer's β-Peptide from Biological Fluids”, Nature, 359, 325-327 (1992).
Sinha, et al., “Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain”, Nature, 402, 537-540 (1999).
Strangeland, et al., “Use of Thiazoles in the Halogen Dance Reaction: Application to the Total Synthesis of WS75624 B”, J. Org. Chem., 69, 2381-2385 (2004).
Ghosh, et al., “Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimer's Disease”, Current Topics in Medicinal Chemistry, 5, 1609-1622 (2005).
Selcoe, D.M., “The Molecular Pathology of Alzheimer's Disease”, Neuron, 6, 487-498 (1991).
Albrecht Brian K.
Andersen Denise Lyn
Bartberger Michael
Brown James
Brown Ryan
Amgen Inc.
McDowell Brian
Prabhakar Reddy G.
Wilson James O
LandOfFree
Beta-Secretase modulators and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-Secretase modulators and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-Secretase modulators and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664063